APLIF (Appili Therapeutics) ROE % Adjusted to Book Value: 0.00% (As of Dec. 2025)


What is Appili Therapeutics ROE % Adjusted to Book Value?

Appili Therapeutics APLIF ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. The stock has 4 warning signs investors should review.

Appili Therapeutics's ROE % for the quarter that ended in Dec. 2025 was 0.00%. Appili Therapeutics's PB Ratio for the quarter that ended in Dec. 2025 was N/A. Appili Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was N/A.

Appili Therapeutics ROE % Adjusted to Book Value Related Terms

Appili Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Appili Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Appili Therapeutics ROE % Adjusted to Book Value Chart

Appili Therapeutics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -25.75 0.00 0.00 0.00 0.00

Appili Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 Negative Equity 0.00 0.00 0.00

APLIF vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Appili Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Appili Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Appili Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Appili Therapeutics's ROE % Adjusted to Book Value falls into.


Appili Therapeutics ROE % Adjusted to Book Value Calculation

Appili Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Appili Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Appili Therapeutics (APLIF) has a ROE % Adjusted to Book Value of 0.00% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Appili Therapeutics and its competitors.
Is Appili Therapeutics' ROE % Adjusted to Book Value too high?
Appili Therapeutics' current ROE % Adjusted to Book Value is 0.00%.
How does Appili Therapeutics' ROE % Adjusted to Book Value compare to VRTX and REGN?
Appili Therapeutics' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Appili Therapeutics and its competitors. Appili Therapeutics's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Appili Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Appili Therapeutics (APLIF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 13% above its estimated fair value. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Appili Therapeutics (APLIF), the current ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Appili Therapeutics Business Description

Other Exchanges APLI:Canada
Address 1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes programs namely ATI-1701, ATI-1801.